Urinary Tract Infections Among Patients of Bladder Outlet Obstruction

Shakya BK1, Jindal RP2, Sahota SK3*, Jindal N4

1Postgraduate, M.Sc MLT Microbiology, Guru Gobind Singh Medical College and Hospital, Faridkot, India; 2Associate Professor and Head, Department of Urology, Guru Gobind Singh Medical College and Hospital, Faridkot, India; 3Postgraduate, M.Sc MLT Microbiology, Guru Gobind Singh Medical College and Hospital, Faridkot, India; 4Professor and Head, Department of Microbiology, Guru Gobind Singh Medical College and Hospital, Faridkot, India.

ABSTRACT

Background: Bladder outlet obstruction (BOO) is defined as blockage at the neck of the urinary bladder. This is one of the most common conditions in elderly men. BOO results from several etiologies, which may be functional or anatomic. However, the main cause of BOO remains benign prostatic hyperplasia (BPH), secondary to BOO and carcinoma prostate. The complication of BOO can be devastating and long term. The resulting obstruction frequently produces lower urinary tract symptoms (LUTS) and becomes the main cause of lower urinary tract infections (LUTI).

Material and Methods: In this cross-sectional study, a total of 100 consecutive patients of BOO who presented to our tertiary care hospital were enrolled in this study. After recording the demographic profile their mid-stream urine samples were collected and cultured for bacterial pathogens. The bacterial isolates were identified using standard microbiological methods and tested against a wide spectrum of antimicrobial agents using Kirby Bauer’s method following the Clinical & Laboratory Standards Institute (CLSI) guidelines.

Results: Out of the 100 patients studied, 78% had BPH, and urine culture was positive in 74%. Most of these patients were more than 50 years of age group (90.5%) (Mean age= 61.2 years). There were 97.3% males and 2.7% of females. BPH was the most common cause of UTI as compared to the other causes of BOO (p=0.00001). Escherichia coli 46(62.1%) was the most common uropathogen causing UTI followed by Klebsiella pneumoniae 12(16.2%), Pseudomonas aeruginosa 10(13.5%), and the gram-positive organisms (Staphylococcus aureus, CoNS, Enterococcus faecalis 2.7% each). The study of their antimicrobial susceptibility showed that antimicrobial resistance to two or more drugs was present in the gram-negative (68/74) and gram-positive (6/74) isolates.

Conclusion: The present study shows that BPH continues to be the most frequent cause of BOO. There is a high prevalence of UTI in these patients which is caused by multidrug-resistance organisms. This study has important implications in the treatment of urinary tract infections among BOO patients in our region.

Key Words: Bladder outlet obstruction (BOO), Benign prostatic hyperplasia (BPH), Multidrug-resistant (MDR), Urinary tract infection (UTI), Lower urinary tract syndrome (LUTS), Uropathogens

INTRODUCTION

Bladder outlet obstruction (BOO) is defined as blockage at the neck of the urinary bladder. This is one of the most common conditions in elderly men.1 As the age expectancy is increasing the number of men affected by BOO is expected to rise. The greatest increase is anticipated in developing countries like India.2 BOO results from several etiologies, which may be functional or anatomic. The various reported causes of BOO are benign prostatic hyperplasia (BPH), carcinoma prostate, bladder stone, bladder carcinoma, posterior urethral valve, dysfunctional voiding, neurogenic-based detrusor-sphincter dyssynergia (DSD), bladder neck stenosis and obstruction from stress urinary incontinence surgery.3,4 However, the main cause of BOO remains benign prostatic enlargement, secondary to BPH and carcinoma prostate. BPH is a condition inevitably associated with ageing. Fifty per cent of men over the age of 40 develop BPH.5,6 In contrast, BOO is a poorly understood condition in females. It is much rare in them as compared to males and has the aetiology of bladder neck stenosis, urethral stricture, urethral diverticulum and retroverted uterus.7
The Complication of BOO can be devastating and long term. BOO can permanently damage all parts of the urinary system. The obstruction frequently produces lower urinary tract symptoms (LUTS) which can have a significant negative impact on the quality of life. There is urine stasis from incomplete voiding and the resultant residual urine serves as the medium for bacterial growth which leads to urinary tract infection (UTI). Lower UTI involves infections from the urinary bladder downward and includes urethritis, cystitis and prostatitis. Asfo-Adjei et al. reported a 76.6% incidence of urinary tract infections among their BOO patients and the main risk factor identified was catheterization. Most of these infections are caused by a few genera of the family Enterobacteriaceae and the common uropathogens reported are Escherichia coli, Pseudomonas spp., Staphylococcus aureus, Enterococcus species, Klebsiella spp. and Proteus spp. The microbes causing infection differ in their susceptibility towards various antimicrobial drugs from place to place and time to time. The emergence of multiple drug resistance strains causing UTI is also escalating. It is a big challenge in our country because of the irrational use of antibiotics. Hence, the present study was undertaken with aim of determining the proportion of UTI and various uropathogens causing it in the clinically suspected patients of BOO attending the urology department of our tertiary care centre. There is a paucity of such studies from this area of Punjab (North India).

MATERIAL AND METHODS

This prospective cross-sectional study was conducted on a total of 100 consecutive patients of BOO who were attending the urology department of our tertiary care centre. Ethical approval of this study was obtained from the institutional review committee (BFUHS/2K19p-TH/8906). After recording the demographic profile of the patients in the prescribed Performa, their urine samples were collected, using all the sterile precautions. The patients were asked to collect midstream urine samples in sterile containers, which were transported to the microbiology department within 2 hours of collection. The urine specimen was processed within 30 minutes of arrival in the laboratory. Specimens were initially inoculated on a standard culture media, Cystine–Lactose–Electrolyte-Deficient (CLED) agar, using a standard calibrated loop. Following incubation in an ambient air incubator at 35-37°C for 18 hours colonies were counted and counts of ≥10⁵ CFU/mL were assessed as significant bacteriuria. The bacterial growth was identified based on their colonial morphology, Gram’s staining, and biochemical reactions which included the Catalase test, slide and tube Coagulase test, Oxidase test, Indole test, MR test, Citrate utilization test, Triple sugar iron test (TSI). Oxidation/fermentation test, Urease test, Nitrate reduction test, VP (Voges-Proskauer) test. The isolated and identified colonies were then tested for antimicrobial susceptibility on Mueller Hinton agar using the Kirby-Bauer disc diffusion method according to Clinical Laboratory Standard Institute (CLSI) guidelines. The antibiotic discs and their concentration used in the study were Ampicillin (2µg), Cefoxitin (30µg), Cefotaxime (30µg), Ceftriaxone (30µg), Ceftazidime (30µg), Cefepime (30µg), Gentamicin (10µg), Amikacin (30µg), Imipenem (10µg), Norfloxacin (10µg), Ciprofloxacin (10µg), Levofloxacin (10µg), Piperacillin-Tazobactam (100/10µg), Amoxicillin-Clavulanic acid (30µg/10µg), Nitrofurantoin (300µg), Vancomycin (30µg), Linezolid (30µg), High-level Gentamicin (120µg), Colistin/Polymyxin B (100 unit) for Staphylococci, MIC (minimum inhibitory concentration) of Vancomycin was determined and value of ≤2 µg/ml was considered as sensitive.

Data so obtained was analyzed using Microsoft Excel software and Statistical Package for the Social Sciences (SPSS). The Chi-square test was employed to study the association of current LUTI status with other factors. The variables were compared using cross-tabulation statistical methods and the p-value <0.05 was considered statistically significant.

RESULTS

Table-1 summarizes the demographic profile of 100 patients who were suspected to have clinical evidence of BOO by the treating urologist. The mean age of the study population was 61.2 years (9-83 years). The maximum patients 83(83%) were more than 50 years of age followed by 5-15 years (9%). Most (93%) of them were males and the females constituted only 7% of the study population. A total of 73% were literate and had education up to 5th standard or more. In terms of occupation, pensioners were predominant (54%) followed by those in jobs (employed) (34%). In the present study, the most common cause of BOO was found to be benign prostatic hyperplasia (78%) followed by prostate cancer (14%), bladder neck stenosis (4%), and posterior urethral valve (2%) (Table-1). There was a history of acute and chronic retention and chronic urinary catheterization in 69%. The most common comorbidity among the patients of BOO observed was hypertension (43%) followed by diabetes (9%).

On culture, significant bacterial growth was obtained in 74(74%). Of these 67(90.5%) were more than 50 years of age. The culture positivity in this age group showed a statistically significant difference from the 5-15 years of age group (p-value: a and b= 0.02). Out of 74 culture-positive patients, 72(97%) were males and 2(2.7%) were females and the difference was statistically significant (p-value: c and d= 0.01). BPH 67(90.5%) was the main cause of LUTI followed by various other causes which also showed a statistically sig-
significant difference (p-value: e and f= 0.000001) (Table 1). Of the 74 positive bacterial cultures, 68(91.9%) showed the growth of gram-negative bacteria while only 6(8.1%) were gram-positives. *E. coli* found to be the most frequent 46(62.1%) isolate followed by *K. pneumonia* 12(16.2%) and *P. aeruginosa* 10(13.5%). The gram-positive bacteria isolated were *S. aureus*, coagulase-negative *staphylococci* (CoNS) and *Enterococcus faecalis* 2(2.7%) each (Figure-1). The result of antimicrobial susceptibility testing of the 74 isolated organisms is shown in (Table-2). *E.coli* which was the most prevalent organism causing UTI in the present study was found to be 100% resistant to Amikacin, all the three 3rd generation and 4th generation cephaplosporins (Cefotaxime, Ceftriaxone, Cefazidime, cefpime) and Ciprofloxacin. This was followed by resistance to Imipenem (73.9%), Norfloxacan and Levofloxacin (60.8% and 54.3% respectively). Resistance to aminoglycosides (Gentamicin and Amikacin) was less than 50%. While Nitrofurantoin was effective in more than 80%, no strain was found to be resistant to colistin. The 12 isolates of *K. pneumoniae* showed an almost similar pattern of resistance as that of *E. coli*. The exception was that *K. pneumoniae* strains were more resistant to Imipenem (83.3%) and even Nitrofurantoain (50%) than those of *E. coli*. All the 10 strains of *P. aeruginosa* showed 100% resistance to Ampicillin, cepha- losporins, Norfloxacin and Ciprofloxacin, and more than 80% resistance to Gentamicin, Amikacin, and Imipenem. Amongst the gram-positive cocci, the resistance to Ampicillin, Aminoglycosides (Amikacin and Gentamicin), and fluoroquinolones (Levofloxacin, Ciprofloxacin, and Norfloxacin) was 100%. But all the strains were sensitive to Vancomycin, and Linezolid. Resistant to two or more drugs was observed in all the gram-negative and gram-positive isolates. Thus, the overall prevalence of multidrug resistance was 100% in our study (Table-2).

**DISCUSSION**

The focus of the present study was to determine the important causes of BOO and the common uropathogen causing LUTI among patients of BOO in our region (North India). We observed that the mean age of our study participants was 61.2 years and 83% were more than 50 years of age. This is similar to the findings of two studies of Gyasi-Sarponget al. In both studies, the mean age was 62 years. Shettyet al. observed it to be 57 years and the range was between 18-80 years. There was a predominance of males (93%) and the male, the female ratio was 13.2 in our study. Other authors have also reported that BOO, more commonly affects men especially those of the old age group, male and female ratio in the study of Katakwar and Thakur was 15.6 which is similar to that of the present study.20 The most frequent cause of BOO in the present study was BPH (78%) which corroborates the findings of Asafo-Adjeiet al. and other authors. Shettyet al. had reported that the most common cause of BOO was BPH and bladder neck stenosis in females. Four of the 7 females of our study were suffering from bladder neck stenosis (Table-1).

The prevalence of UTI among the patients of BOO in our study was 74% and the maximum positive cultures were obtained in patients of more than 50 years of age followed by 5-15 years (age group). Statistically, the difference between the two age groups was significant (p-value: a and b= 0.0003) Table 1. In a study, Gyasi-Sarpong et al. reported a 76% prevalence of UTI among BOO patients of more than 70 years of age. Jarvis et al. also observed that the prevalence of UTI was often indicative of BOO secondary to BPH, especially in elderly men.

A wide range of bacterial organisms was observed to cause UTI in the present study. There was a predominance of members of the family Enterobacteriaceae and *E. coli* was the most frequent (62.1%). The other isolates identified were Klebsiella spp. (16.2%), Pseudomonas spp. (13.5%) and Staphylococcus spp. (5.4%) and Enterococci (5.4%). This is similar to the studies of Asafo-Adjeiet al. and Ahmed et al. However, Enterococcus faecalis which was found to be an important gram-positive uropathogen in our study was not isolated in the study of Asfo-Adjeiet al. In another study Klebsiella spp. (36.6%) and *P. aeruginosa* (27%) were the most prevalent organisms. This variation in the aetiology of UTI could be because of differences in the periods of the studies, in the places/regions/countries of the study, and the study population.

All the gram-positive and gram-negative organisms causing UTI in the present study were found to be resistant to two or more drugs. The alarming finding was that all (100%) strains of *E. coli* resistant to Ampicillin, Cefotaxime, Ceftriaxone, Cefepime and Ciprofloxacin. They also showed very high resistance to Imipenem (73.9%). Only Colistin and Nitrofurantoin were found to be effective with the sensitivity of 100% and 80.5% respectively. Hussain et al. also reported the maximum resistance of *E.coli* to Ampicillin, 3rd generation cephaplosporins, Norfloxacan and Gentamycin. Asfo-Adjeiet al observed high resistance of *E. coli* to fluoroquinolones. The strains of *K. pneumoniae* of the present study had shown an even higher level of resistance as compared to those of *E. coli* which also corroborates the findings of Hussain et al. However, a reverse trend was observed by Ranbeeret al. They found 89% sensitivity to Gentamycin, 93% to Imipenem and 98% to Nitrofurantoin. The isolated strains of *P. aeruginosa* also showed a very high level of resistance to all antimicrobials agents including Imipenem (80%). A similar pattern was observed in the study of Asfo-Adjeiet al. This could be because UTI is often treated empirically which results in inappropriate and non-judicious use of these.
high-end antimicrobial agents leading to MDR (multiple drug resistance) infections in patients with UTI.

In our study, there were only four strains of Staphylococcus species and two of them were resistant to Cefoxitin. These two methicillin-resistant Staphylococcus aureus (MRSA) strains were showed resistance to Ampicillin and aminoglycosides. However, these were found to be sensitive to Vancomycin and Linezolid. Thus, we were left with the option of treatment of these infections by Linezolid or Vancomycin. Enterococci are an important cause of UTI and in the present study, Enterococcus faecalis was found to be causing significant bacteriuria in two patients. Both these strains were highly resistant. They showed sensitivity only to Vancomycin and Linezolid. It is an alarming situation as Vancomycin-Resistant Enterococcus (VRE) causing UTI are difficult to manage. Linezolid, the oral drug could be used but only 30% of each dose of it is excreted in the urine.26

**CONCLUSION**

The present study confirms that BPH continues to be the most common cause of BOO and UTI caused by multi drug-resistant organisms is highly prevalent in these patients for the adequate treatment of these patients, appropriate antibiotics selected after urine culture and antimicrobial susceptibility testing should be used. This could also help to contain the problem of drug resistance. The drug monitoring system that augments drug administration and associates a more personalized methodology to recommended treatment may also help.

**Conflict of interest**

The authors declare no conflicts of interest.

**ACKNOWLEDGEMENT**

We are very thankful to all the study participants for being a part of this study. We have many thanks to lecturers and friends who helped us during this research. We would like to thanks the microbiology department of Guru Gobind Singh Medical College and Hospital, Faridkot.

**Funding**

No funding was received to perform this study.

**Author’s contribution**

Study conception and design: Jindal N. Data collection: Shakya BK and Sahota SK. Laboratory work: Shakya BK. Analysis and interpretation of data: Jindal RP, Shakya BK and Sahota SK. Final drafting of manuscript: Jindal RP, Shakya BK, Jindal N and Sahota SK. All authors commented and approved the final manuscript.

**REFERENCES**

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. The J Urolo. 1984 Sep 1;132(3):474-9.
2. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. Bri J Urol Int. 2011 Oct;108(7):1132-8.
3. Wein AJ, Levin RM, Barrett DM. Voiding function: relevant anatomy, physiology and pharmacology. In: Gillenwater JY, Grayhack JT, Howards SS, Duckett JD editors. Adult and Pediatric Urology.1st ed. Chicago: Yearbook Medical Publishers; 1987. p.800-62.  
4. Dmochowski RR. Bladder outlet obstruction: etiology and evaluation. Rev Urol. 2005;7(Suppl 6):S3-13.  
5. Holund B. Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol. 1980 Jan 1;14(1):29-35.  
6. Franks LM. Benign nodular hyperplasia of the prostate- a review. Ann R Coll Surg Engl. 1953;14(2):92-106.  
7. Carr LK, Webster GD. Bladder outlet obstruction in women. Urol Clin Nor Ame. 1996 Aug 1;23(3):385-91.  
8. Shetty A, Pandit A, Majeed A. Incidence and aetiology of bladder outlet obstruction in Mangalore, Karnataka. Ame Health Ssc. 2014;1(1):65-7.  
9. Gyasi-Sarpong CK, Nkrumah B, Yanli EM, Appiah AA, Aboah K, Azorliade R et al. Resistance pattern of uropathogenic bacteria in males with lower urinary tract obstruction in Kumasi, Ghana. Afr J Microbiol Res. 2014 Sep;8(36):3324-9.  
10. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. Bri J Urol Int. 2008;101:1388-95.  
11. Irwin DE, Milsom I, Kopp Z, Abrams P. Symptom bother and healthcare-seeking behaviour among individuals with overactive bladder. Eur Urol. 2008;53:1029-37.  
12. Asafo-Adjei K, Mensah JE, Labi AK, Dayie NT, Donkor ES. Urinary tract infections among bladder outlet obstruction patients in Accra, Ghana: aetiology, antibiotic resistance, and risk factors. Dis. 2018 Sep;6(3):65.  
13. Behzadi P, Behzadi E, Yazdanbod H, Aghapour R, Cheshme MA, Omran DS. A survey on urinary tract infections associated with the three most common uropathogenic bacteria. Medica. 2010 Apr;5(2):111.  
14. Beyene G, Tsegaye W. Bacterial uropathogens in urinary tract infection and antibiotic susceptibility pattern in Jimma university specialized hospital, southwest Ethiopia. Ethiop J Health Sci. 2011;21(2):141-6.  
15. Gupta V, Yadav A, Joshi RM. Antibiotic resistance pattern in uropathogenic. Ind J Med Microb. 2002 Apr 1;20(2):96.  
16. Collee JG, Miles S, Watt B. Tests for identification of bacteria. In: Collee JG, Marmion BP, Fraser AG, Simmons A editors. Mackie and McCartney practical medical microbiology. 14th ed. London: Churchill Livingstone; 2015;131-50.  
17. Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn WC Jr. The Enterobacteriaceae. In: Color atlas and textbook of diagnostic microbiology. 7th ed. Philadelphia: Wolters Kluver. 2017.p.214-80.  
18. CLSI. Performance standards for Antimicrobial Susceptibility Testing. 30th ed. supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2020.  
19. Gyasi-Sarpong CK, Yanli EM, Idriss A, Arhin AA, Aboah K, Azorliade R et al. Bacterial urinary tract infections among males
with lower urinary tract obstruction at KomfoAnokye. Open J Urol. 2012;2:131-6.
20. Katakwar P, Thakur R. Clinical study and management of bladder outlet obstruction. Int Surg J. 2017 Mar 25;12(4):1272-5.
21. Jarvis TR, Chughtai B, Kaplan SA. Bladder outlet obstruction and BPH. Curr Blad Dysf Rep. 2014 Dec 1;9(4):372-8.
22. Ahmad S. Pattern of urinary tract infection in Kashmir and antimicrobial susceptibility. Bangladesh Med Res Coun Bull. 2012;38(3):79-83.
23. Taiwo SS, Aderounmu AO. Catheter-associated urinary tract infection: aetiology agents and antimicrobial susceptibility pattern in LadokeAkintola University Teaching Hospital, Osogbo, Nigeria. Afr J Biomed Res. 2006;9(3):472.
24. Hussain S. Increasing Antibiotic Resistance in the Uropathogens. Asia J Pharr. 2019 Feb 9:13(01).
25. Singh RK, Haque SS. Antibiotic susceptibility patterns in commonly isolated pathogens in east Indian population. Adv Biochem Biotechnol. 2019 Mar 20.
26. Pontefract B, Madaras-Kelly K. Linezolid for Treatment of Urinary Tract Infections Caused by Vancomycin-resistant Enterococci. Open Forum Infect Dis. 2019 Oct 23;6(2):537.

Table 1: Demographic and clinical features of the study participants.

| Age (years) | N=100 | Z=74 | P-value |
|-------------|-------|------|---------|
| 5-15        | 9(9%) | 4(5.4%) | a and b = 0.0003 |
| 16-40       | 3(3%) | 1(1.4%) | |
| 41-50       | 5(5%) | 2(2.7%) | |
| >50         | 83(83%) | 67(90.5%) | |

| Gender     | N=100 | Z=74 | P-value |
|------------|-------|------|---------|
| Male       | 93(93%) | 72(97.3%) | c and d = 0.01 |
| Female     | 7(7%) | 2(2.7%) | |

| Education status | N=100 | Z=74 | P-value |
|------------------|-------|------|---------|
| Literate         | 73(73%) | 59(79.7%) | |
| Illiterate       | 27(27%) | 15(20.2%) | |

| Occupation     | N=100 | Z=74 | P-value |
|----------------|-------|------|---------|
| Unemployed     | 12(12%) | 10(13.5%) | |
| Employed       | 34(34%) | 15(20.3%) | |
| Pensioner      | 54(54%) | 49(66.2%) | |

| Cause of BOO    | N=100 | Z=74 | P-value |
|-----------------|-------|------|---------|
| BPH             | 78(78%) | 67(90.5%) | e and f = 0.00001 |
| Prostate cancer | 14(14%) | 5(6.8%) | |
| Bladder neck stenosis | 4(4%) | 1(1.4%) | |
| Posterior urethral valve | 2(2%) | 0 | |
| Bladder carcinoma | 1(1%) | 1(1.4%) | |
| Bladder stone   | 1(1%) | 0 | |

| Comorbidities   | N=100 | Z=74 | P-value |
|-----------------|-------|------|---------|
| Hypertension    | 42(42%) | 7(9.4%) | |
| Diabetes        | 29(29%) | 3(4%) | |
| Stroke          | 5(5%) | 1(1.4%) | |
| Other           | 2(2%) | 0 | |

BPH = benign prostatic hyperplasia, BOO= bladder outlet obstruction. “N” = number of study subjects, “Z” = number of cultures positive, “f” = Causes of BOO other than BPH.
Table 2: In vitro antibiotic susceptibility of isolated uropathogens.

| ANTIBIOTICS | EC(n=46) | KP(n=12) | PA(n=10) | SA(n=2) | CoNS(n=2) | EF(n=2) |
|-------------|----------|----------|----------|---------|-----------|---------|
| Ampicillin  | 46(100%) | 12(100%) | 10(100%) | 2(100%) | 2(100%)   | 2(100%) |
| Cefotaxime  | 46(100%) | 12(100%) | 10(100%) | NT      | NT        | NT      |
| Ceftriaxone | 46(100%) | 12(100%) | 10(100%) | NT      | NT        | NT      |
| Ceftazidime | 46(100%) | 12(100%) | 8(80%)   | NT      | NT        | NT      |
| Gentamicin  | 20(43.4%)| 6(50%)   | 8(80%)   | 2(100%) | 2(100%)   | 1(50%)  |
| Amikacin    | 19(41.3%)| 6(50%)   | 8(80%)   | 2(100%) | 2(100%)   | 2(100%) |
| Nitrofurantoin | 9(19.5%) | 6(50%)   | 6(60%)   | NT      | NT        | 2(100%) |
| Norfloxacin | 28(60.8%)| 8(66.6%) | 8(80%)   | 0(0%)   | 0(0%)     | 2(100%) |
| Ciprofloxacin| 46(100%)| 12(100%)| 10(100%)| 2(100%)| 2(100%)  | 2(100%) |
| Levofoxacin | 25(54.3%)| 7(58.3%)| NT       | 2(100%)| 2(100%)  | 2(100%) |
| Amoxicillin+cavulanic acid | 25(54.3%)| 7(58.3%)| NT       | NT      | NT        | NT      |
| Vancomycin  | NT       | NT       | NT       | 0(0%)   | 0(0%)     | 0(0%)   |
| Linezolid   | NT       | NT       | NT       | 0(0%)   | 0(0%)     | 0(0%)   |
| High level Gentamicin | NT | NT | NT | NT | 0(0%) | NT |
| Colistin/polymyxin B | 0(0%) | 0(0%) | 0(0%) | NT | NT | NT |

EC= *E. coli*, KP= *K. pneumoniae*, PA= *P. aeruginosa*, SA= *S. aureus*, CoNS= coagulase negative staphylococcus, EF= *Enterococcus faecalis*, NT= Not tested.

Figure 1: Uropathogens isolated.